The Board has an experienced multidisciplinary management and advisory team with a strong, proven record of developing and successful product commercialisation.
Otto Buttula
Executive Chairman
Mr Buttula has had extensive experience and success in investment research, funds management and information technology and has held directorships in a number of public companies. Mr Buttula’s executive experience includes co-founder and CEO and Managing Director of IWL Limited, an online financial services company that listed on the ASX in 1999. The company grew from a market capitalisation of $48 million at listing before a takeover in 2007 by Commonwealth Bank of Australia for $373 million. Mr Buttula also founded and was Managing Director of Investors Mutual, prior to which he was a co-founder and director of Lonsdale Securities Limited.
Following his completion of executive duties, Mr Buttula was Non-Executive Chairman of platform and stockbroking provider Investorfirst Limited and led the acquisition of HUB24 Limited (ASX: HUB). More recently, he served on the Board as a non-executive director and Head of Audit & Risk at Imugene Limited (ASX: IMU) between 2014 and 2016.
Glenn Gilbert
Managing Director
A pragmatic and commercial driven leader with over 17 years of experience in the healthcare sector across domestic and international markets. His expertise spans strategy, manufacturing and sales, with a sharp focus on disciplined execution through culture, relationships and planning. Glenn has held leadership roles at Seqirus, a CSL company (ASX:CSL), and recently at Medical Developments International (ASX:MVP) with extensive business experience across the UK, Europe, Asia, North and South America. He specialises in mergers and acquisitions, corporate development, operations, intellectual property and legal portfolios. Glenn also holds a Master of Business Administration (MBA), Graduate Certificate in Corporate Management and a Bachelor of Science degree.
Initially, Glenn’s objective is to lead the growth ambitions of Rhythm Biosciences by commercialising its pioneering ColoSTAT® technology.
Lou Panaccio
Non-Executive Director
A chartered accountant with extensive management experience in business and healthcare services. He is currently on the boards of ASX listed companies Sonic Healthcare Limited and Avita Medical Limited. Lou is also on the board of NeuralDX Limited and Unison Housing Limited.
Lou has more than twenty years’ experience as a board member of both public and private, for profit and not for profit companies. Previously, Lou was the CEO of Melbourne Pathology and Monash IVF, and also executive Chairman of Health Networks Australia.
Trevor Lockett PhD
Technical Director
A molecular biologist by trade, Trevor Lockett received his PhD in biochemistry from the University of Adelaide and postdoctoral experience at the Rockefeller University in New York. With over 30 years of research experience, predominantly at the CSIRO, Trevor has led large, multidisciplinary research efforts in the areas of prostate cancer gene therapy, colorectal cancer prevention and the promotion of gastrointestinal health. In his role as Theme Leader, Colorectal Cancer and Gut Health, Trevor oversaw the research efforts leading to the technology that is to become ColoSTAT™.
Trevor is an inventor of seven active patent families, all of which have been licensed. Trevor has previously served on the leadership executive team of business units within CSIRO and has a strong commitment to improving human health and wellbeing through the translation and commercialisation of scientific discovery into innovative products and services.
Dr Rachel David
Non Executive Director
Rachel is an experienced senior health and financial services sector executive with a deep understanding of the complex interplay between government, business, media and the community which underpin the economic challenges and opportunities faced by Australia’s health care system. Rachel’s career has spanned over 25 years during which she has delivered significant value by promoting policy change to address the significant economic problems and market failures in healthcare, particularly relating to evidence-based practice and access to new technologies.
Rachel holds a Bachelor of Medicine, Bachelor of Surgery (MBBS), Master of Business Administration (MBA) and is a graduate of the Australian Institute of Company Directors. Rachel is currently the Chief Executive Officer (CEO) of Private Healthcare Australia (PHA), the peak organisation representing Australia’s 23 major health funds, which represent 98% of the industry. This includes the two major listed companies, Medibank and nib. Primarily a policy and advocacy organisation, PHA works with Australian Governments on ensuring policy and regulatory settings are enabling sustainability and growth in the private health sector. Prior roles include Senior Director Government Affairs, Policy and Market Access for Johnson & Johnson, senior roles within McKinsey, CSL and Pfizer (formerly Wyeth). Further, Dr David has held direct Government roles within the Office of the Federal Minister for Health and Ageing.